Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Key differences found between pediatric- and adult-onset MS

Publish date:: February 28, 2020

Key clinical point: Pediatric-onset MS has a unique phenotype, and the choice of treatment may influence the frequency of fatigue and mood disorders among these patients.

Major finding: Anxiety and fatigue were associated with disease-modifying therapy efficacy in pediatric-onset MS.

Study details: An analysis of data from MS Partners Advancing Technology and Health Solutions (MS-PATHS).

Disclosures: Biogen sponsors MS-PATHS. Dr. Rensel has received funding from several companies, including Biogen, Novartis, Serono, and Teva.

Citation:

Rensel M et al. ACTRIMS 2020, Abstract P042.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,